DRSAb对缺血再灌注损伤大鼠肾脏的保护作用
Protective effects of DRSAb on ischemia reperfusion induced renal injury in rats

DOI: 10.6040/j.issn.1671-7554.0.2017.493

Keywords: 缺血再灌注损伤,钠钾ATP酶,PI3K/AKT,PKCε,DR区特异性抗体,
DR region specific antibody,Ischemia/reperfusion,PI3K/AKT,Na⁺/K⁺-ATPase,PKCε

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Yue TL, Wang C, Gu JL, et al. Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart[J]. Circ Res, 2000, 86(6): 692-699.
[2]	Kang JH, Toita R, Kim CW, et al. Protein kinase C(PKC)isozyme-specific substrates and their design[J]. Biotechnol Adv, 2012, 30(6): 1662-1672.
[3]	Malek M, Nematbakhsh M. Renal ischemia/reperfusion injury; from pathophysiology to treatment [J]. J Renal Inj Prev, 2015, 4(2): 20-27.
[4]	Aizman O, Aperia A. Na(+)/K(+)-ATPase as a signal transducer[J]. Ann N Y Acad Sci, 2003, 986(1): 489-496.
[5]	Chen XD, Su MY, Chen TT, et al. Oxidative stress affects retinal pigment epithelial cell survival through epidermal growth factor receptor/AKT signaling pathway[J]. Int J Ophthalmol, 2017, 10(4): 507-514.
[6]	Ma ZG, Xia HQ,Cui SL, et al. Attenuation of renal ischemic reperfusion injury by salvianolic acid B via suppressing oxidative stress and inflammation through PI3K/Akt signaling pathway [J]. Braz J Med Biol Res, 2017, 50(6): e5954. doi: 10.1590/1414-431X20175954.
[7]	Newton AC, Brognard J. Reversing the paradigm:protein kinase C as a tumor suppressor[J]. Trends Pharmacol Sci, 2017, 38(5): 438-447.
[8]	Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning[J]. Cardiovasc Res, 2006,70(2): 240-253.
[9]	Yao H, Han X, Han X. The cardioprotection of the insulin-mediated PI3K/Akt/mTOR signaling pathway[J]. Am J Cardiovasc Drugs, 2014, 14(6): 433-442.
[10]	易善红. 人促红细胞生成素对肾脏缺血再灌注的保护作用[J]. 免疫学杂志, 2007, 23(1): 49-51. YI Shanhong. Protective activity of human erythropoietin against renal ischemia-reperfusion injury[J]. Immunological Journal, 2007, 23(1): 49-51.
[11]	Xu KY, Takimoto E, Fedarko NS. Activation of(Na+/+ K+)-ATPase induces positive inotropy in intact mouse heart in vivo[J]. Biochem Biophys Res Commun, 2006, 349(2): 582-587.
[12]	Lee SG, Su ZZ, Emdad L, et al. Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling [J]. Oncogene, 2008, 27(8): 1114-1121.
[13]	Huang P, Sun Y, Yang J, et al. The ERK1/2 signaling pathway is involved in sulfur dioxide preconditioning-induced protection against cardiac dysfunction in isolated perfused rat heart subjected to myocardial ischemia/reperfusion[J]. Int J Mol Sci, 2013, 14(11): 22190-22201.
[14]	Zheng J, Koh X, Hua F, et al. Cardioprotection induced by Na<sup>+</sup>/K<sup>+</sup> ATPase activation involves extracellular Signal regulated kinase1/2 and phosphoinositide 3-kinase /AKT pathway[J]. Cardiovasc Res, 2011, 89(1): 51-59.
[15]	Gong HL, Sun JJ, Xue WJ, et al. Protective effect of truncated Na<sup>+</sup>/K<sup>+</sup>-ATPase b on ischemia/reperfusion-induced renal injury in rats [J]. Exp Biol Med(Maywood), 2014,239(6):677-685.
[16]	Guerreroorriach JL, Belmonte JJE, Fernandez AR, et al. Cardioprotection with halogenated gases: how does it occur? [J]. Drug Des Devel Ther, 2017, 16(11): 837-849.
[17]	Guo XQ, Cao YL, Hao F, et al. Tangeretin alters neuronal apoptosis and ameliorates the severity of seizures in experimental epilepsy-induced rats by modulating apoptotic protein expressions, regulating matrix metalloproteinases, and activating the PI3K/Akt cell survival pathway [J]. Adv Med Sci, 2017, 62(2): 246-253.
[18]	Yao H, Han X, Han X. The cardioprotection of the insulin-mediated PI3K/Akt/mTOR signaling pathway [J]. Am J Cardiovasc Drugs, 2014, 14(6): 433-442.
[19]	Peng Y, Pu J, Tang C, et al. Curcumin inhibits heat-induced apoptosis by suppressing NADPH oxidase 2 and activating theAkt/mTOR signaling pathway in bronchial epithelial cells[J]. Cell Physiol Biochem, 2017, 41(5): 2091-2103.
[20]	Antal CE, Newton AC. Tuning the signaling output of protein kinase C.[J]. Biochem Soc Trans, 2014, 42(6): 1477-1483.
[21]	Newton AC, Antal CE, Steinberg SF. Protein kinase C mechanisms that contribute to cardiac remodeling[J]. Clin Sci, 2016, 130(17): 1499-1510.
[22]	Ferreira JC, Brum PC, Mochly-Rosen D.βIIPKC and εPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure [J]. J Mol Cell Cardiol, 2011, 51(4): 479-484.
[23]	Madonna R, Bolli R, Rokosh G, et al. Targeting phosphatidylinositol 3-kinase-Akt through hepatocyte growth factor for cardioprotection [J]. J Cardiovasc Med, 2013, 14(4): 249-253.
[24]	Yu ZH, Cai M, Xiang J, et al. PI3K/Akt pathway contributes to neuroprotective effect of Tongxinluo against focal cerebral ischemia and reperfusion injury in rats [J]. J Ethnopharmacol, 2016, 2(181): 8-19.
[25]	Simkhovich BZ, Przyklenk K, Kloner RA. Role of protein kinase C in ischemic “conditioning”: from first evidence to current perspectives[J]. J Cardiovasc Pharmacol Ther, 2013, 18(6): 525-532.

Full-Text